for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneus Ltd

RGS.AX

Latest Trade

0.10AUD

Change

0.01(+5.56%)

Volume

120,000

Today's Range

0.10

 - 

0.10

52 Week Range

0.06

 - 

0.20

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.09
Open
0.10
Volume
120,000
3M AVG Volume
1.54
Today's High
0.10
Today's Low
0.10
52 Week High
0.20
52 Week Low
0.06
Shares Out (MIL)
253.40
Market Cap (MIL)
26.39
Forward P/E
--
Dividend (Yield %)
--

Next Event

Regeneus Ltd Annual Shareholders Meeting

Latest Developments

更多

Regeneus Announces Positive Preclinical Trial Results For Progenza

Regeneus Appointed Leo Lee As CEO

Regeneus Says Chinese Patent Granted For Biomarkers To Monitor Disease Progression For Stem Cell Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneus Ltd

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

Industry

Biotechnology & Drugs

Contact Info

Ground floor, 25 Bridge St

+61.2.94998010

http://www.regeneus.com.au/

Executive Leadership

Barry G. Sechos

Non-Executive Chairman of the Board

Leo Lee

Chief Executive Officer, Director

John Bird

Chief Financial Officer and Operations Officer

Graham Vesey

Chief Scientific Officer, Executive Director

Sandra McIntosh

Office/Human Resources Manager, Company Secretary

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1,052.79
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-160.12

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up